Tobacco harm reduction with vaporised nicotine (THRiVe): the study protocol of an uncontrolled feasibility study of novel nicotine replacement products among people living with HIV who smoke

Bell, Stephanie, Dean, Judith, Gilks, Charles, Boyd, Mark A., Fitzgerald, Lisa, Mutch, Allyson, Baker, Peter, Neilsen, Graham and Gartner, Coral E. (2017) Tobacco harm reduction with vaporised nicotine (THRiVe): the study protocol of an uncontrolled feasibility study of novel nicotine replacement products among people living with HIV who smoke. International Journal of Environmental Research and Public Health, 14 7: . doi:10.3390/ijerph14070799


Author Bell, Stephanie
Dean, Judith
Gilks, Charles
Boyd, Mark A.
Fitzgerald, Lisa
Mutch, Allyson
Baker, Peter
Neilsen, Graham
Gartner, Coral E.
Title Tobacco harm reduction with vaporised nicotine (THRiVe): the study protocol of an uncontrolled feasibility study of novel nicotine replacement products among people living with HIV who smoke
Journal name International Journal of Environmental Research and Public Health   Check publisher's open access policy
ISSN 1660-4601
1661-7827
Publication date 2017-07-18
Year available 2017
Sub-type Article (original research)
DOI 10.3390/ijerph14070799
Open Access Status DOI
Volume 14
Issue 7
Total pages 12
Place of publication Basel, Switzerland
Publisher M D P I AG
Language eng
Subject 2739 Public Health, Environmental and Occupational Health
2307 Health, Toxicology and Mutagenesis
Abstract Smoking is a leading cause of morbidity and premature mortality among people living with HIV (PLHIV), who have high rates of tobacco smoking. Vaporised nicotine products (VNPs) are growing in popularity as a quit aid and harm reduction tool. However, little is known about their acceptability and use among PLHIV. Using a pragmatic, uncontrolled, mixed methods design this exploratory clinical trial aims to examine the feasibility of conducting a powered randomised clinical trial of VNPs as a smoking cessation and harm reduction intervention among vulnerable populations, such as PLHIV who smoke tobacco. Convenience sampling and snowball methods will be used to recruit participants (N = 30) who will receive two VNPs and up to 12 weeks’ supply of nicotine e-liquid to use in a quit attempt. Surveys will be completed at weeks 0 (baseline), 4, 8, 12 (end of treatment) and 24 (end of the study) and qualitative interviews at weeks 0 and 12. As far as we are aware, this feasibility study is the first to trial VNPs among PLHIV for smoking cessation. If feasible and effective, this intervention could offer a new approach to reducing the high burden of tobacco-related disease among PLHIV and other vulnerable populations.
Keyword E-cigarettes
Feasibility
Harm reduction
HIV
Smoking
Tobacco
Vaporised nicotine
VNPs
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
School of Public Health Publications
Admin Only - School of Public Health
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 01 Aug 2017, 00:11:40 EST by System User on behalf of Learning and Research Services (UQ Library)